Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs 744

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 744 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Pipeline programs

Page 7 of 16

  1. EXENATIDE , VERAPAMIL

    Disc Medicine

    type 1 diabetes mellitus

    phase 2 small molecule active

    1 trial

  2. Eat Well Live Well Nutrition Program

    Grace Therapeutics

    Diabetes or Diabetes Prevention

    phase 2 other completed

    1 trial

  3. Evogliptin

    Samsung Bioepis NL B.V.

    Type2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  4. External Chinese medicine

    Universal Integrated

    Diabetic Foot

    phase 2 small molecule active

    1 trial

  5. Fasiglifam

    Takeda

    Type 2 Diabetes Mellitus

    phase 2 small molecule terminated

    2 trials

  6. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  7. GIP/GLP-1a

    United Therapeutics Europe Ltd

    Non-Alcoholic Fatty Liver Disease

    phase 2 small molecule active

    1 trial

  8. GK1-399 (formerly TTP399)

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  9. GSBR-1290

    Structure Therapeutics

    Overweight or Obesity

    phase 2 small molecule completed

    1 trial

  10. GSK2330672

    ELITE PHARMACEUTICALS INC /NV/

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  11. GWP42004

    Jazz Pharmaceuticals Ireland Limited

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  12. GZR102

    Gan & Lee Pharmaceuticals.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  13. Grafalon 20 mg/ml koncentrát pro infuzní roztok

    The George Institute

    Type 1 diabetes

    phase 2 small molecule active

    1 trial

  14. High Dose SAB-142

    SAB Biotherapeutics

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  15. Humalog

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  16. Humalog

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  17. I8F-MC-GPIG

    Eli Lilly Co.

    Chronic Kidney Disease, CKD, Obesity, Overweight, T2D, Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  18. ISIS 113715

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    5 trials

  19. ISIS-APOCIIIRX

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes

    phase 2 small molecule terminated

    1 trial

  20. ISIS-FGFR4RX

    IONIS PHARMACEUTICALS INC

    Obesity

    phase 2 small molecule completed

    1 trial

  21. ISIS-GCCRRx

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  22. ISIS-GCGRRx

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  23. ISIS-GCGRRx - Dose Level 1

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  24. ISIS-GCGRRx- Dose Level 1

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  25. ISIS-PTP1BRx

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  26. IW-1973

    Akebia Europe Limited

    Type 2 Diabetes Mellitus With Diabetic Nephropathy

    phase 2 small molecule completed

    1 trial

  27. IW-1973

    Cyclerion Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  28. IW-9179

    IRONWOOD PHARMACEUTICALS INC

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  29. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  30. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type II

    phase 2 small molecule completed

    1 trial

  31. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    1 trial

  32. Investigational new drug company code: BGS649

    Mereo BioPharma Group plc

    Obese Hypogonadotropic Hypogonadism

    phase 2 small molecule terminated

    1 trial

  33. Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy

    Eledon Pharmaceuticals

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  34. J1I-MC-GZBU

    Eli Lilly Co.

    Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  35. J1R-MC-GZFD

    Eli Lilly Co.

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  36. JMKX000623

    Jemincare

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule active

    1 trial

  37. Jiangtang Tiaozhi recipe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type2 Diabetes

    phase 2 small molecule active

    1 trial

  38. K-001-201

    The George Institute

    Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

    phase 2 small molecule active

    1 trial

  39. KAI-7535

    Kailera Therapeutics

    Obesity

    phase 2 small molecule active

    2 trials

  40. KVD001 Injection

    Kalvista Pharmaceuticals (Ireland) Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    2 trials

  41. LB54640

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule completed

    1 trial

  42. LGD-6972-5 mg

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  43. LIK066

    Novartis Pharmaceuticals

    Obese Patients With Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  44. LX4211 Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  45. LX9211

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  46. Ladarixin, Placebo to match Ladarixin

    Dompe' Farmaceutici S.p.A.

    Recent onset Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  47. MB07803

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  48. MK-6024-017

    Merck Sharp and Dohme

    Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

744 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.